Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Investor Presentation (October 2023)
29 slides from Jasper Therapeutics's investor presentation, Oct 10, 2023
Slide 1: Jasper Therapeutics October 2023
Briquilimab is an investigative drug and is not approved for any indication 1 Jasper Therapeutics NASDAQ: JSPR October 2023 Exhibit 99.1
Slide 2: Safe Harbor Statements
2 Briquilimab is an investigative drug and is not approved for any indication Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements. All statements other than statemen
Slide 3: Focused on new therapeutics for diseases driven by mast or stem cells
3 Briquilimab is an investigative drug and is not approved for any indication Jasper is focused on the development of new therapeutics targeting significant unmet clinical needs in diseases driven by mast or stem cells • Jasper is developing briquilimab across multiple mast cell mediated diseases, i
Slide 4: SCF blockade drives differential impact on mast cells and stem cells
4 Briquilimab is an investigative drug and is not approved for any indication SCF blockade drives differential impact on mast cells and stem cells MAST CELLS (MC) STEM CELLS (HSC) MC Apoptosis HSC Differentiation APOPTOTIC MC MC MC MC Apoptotic MC Apoptotic MC Apoptotic MC Stem Cell Factor (SCF) Bri
Slide 5: Mast cells are key drivers of inflammatory response in allergic and dermatologic diseases
5 Briquilimab is an investigative drug and is not approved for any indication Mast cells are key drivers of the inflammatory response in a number of allergic and dermatologic diseases Theoharides et al. N Engl J Med. (2015) • Mast cells are the most potent drivers of inflammatory response in skin, l
Slide 6: Depletion of mast cells by anti-c-Kit antibody blockade is a novel approach
6 Briquilimab is an investigative drug and is not approved for any indication Depletion of mast cells by anti - c - Kit monoclonal antibody blockade is a novel approach to treat urticarias and other mast cell mediated diseases 1 Moller C et al. Blood (2005) 2 Hundley TR et al. Blood (2004) 3 Arnold
Slide 7: Briquilimab potently blocks c-Kit signaling leading to durable mast cell depletion
7 Briquilimab is an investigative drug and is not approved for any indication Briquilimab potently blocks c - Kit signaling leading to durable mast cell depletion 1 Jasper internal data • Briquilimab is an aglycosylated IgG1 anti c - Kit antibody with high affinity to c - Kit (Kd <5pm) • Briquilimab
Slide 8: Single subcutaneous injection significantly depletes mast cells in humans
8 Briquilimab is an investigative drug and is not approved for any indication Briquilimab delivered with a single subcutaneous injection significantly depletes mast cells in humans above 0.8 mg/kg threshold 1 Jasper internal data (Phase 1a, healthy volunteer study); Dose is adjusted to body weight (
Slide 9: Favorable pharmacokinetic properties may enable optimal biologic dosing
9 Briquilimab is an investigative drug and is not approved for any indication Briquilimab’s favorable pharmacokinetic properties may enable optimal biologic dosing 1 Jasper internal data (Phase 1a, healthy volunteer study) • Briquilimab is designed to minimize unwanted c - Kit - related effects • Su
Slide 10: Safety profile to date supports development in a variety of mast cell diseases
10 Briquilimab is an investigative drug and is not approved for any indication Briquilimab safety profile to - date supports development in a wide variety of mast cell diseases • c - Kit is expressed on mast cells, hemopoietic stem cells, melanocytes, taste buds, spermatogonia and Cajal (GI) cells,
Slide 11: Briquilimab in Chronic Urticaria
Briquilimab is an investigative drug and is not approved for any indication 11 11 Briquilimab in Chronic Urticaria
Slide 12: Briquilimab Phase 1b/2a in patients with CSU
12 Briquilimab is an investigative drug and is not approved for any indication Briquilimab Phase 1b/2a in patients with Chronic Spontaneous Urticaria (CSU) Study Goal: identify the optimal therapeutic doses & dosing frequency of subcutaneous briquilimab to inform future registrational trials Key Obj
Slide 13: Phase 1b/2a dose levels selected around mast cell depletion threshold
13 Briquilimab is an investigative drug and is not approved for any indication Phase 1b/2a dose levels selected to generate data below and above mast cell depletion threshold observed in Phase 1 healthy volunteer study *Jasper internal data (Phase 1a, healthy volunteer study); Skin biopsies were use
Slide 14: Dose frequencies selected to align with mast cell recovery in skin
14 Briquilimab is an investigative drug and is not approved for any indication Phase 1b/2a dose frequencies selected to align with mast cell recovery in the skin, which typically takes 3 months or longer 1 Maurer et al, GA²LEN Global Urticaria Forum – Berlin, December 6, 2022 • Single administration
Slide 15: Briquilimab Phase 1b/2a Chronic Spontaneous Urticaria study design
15 Briquilimab is an investigative drug and is not approved for any indication Part 1 (n=6) Part 2 (n=28) Part 3 (n=4) • CSU diagnosis ≥ 6 mos. • UAS7 ≥ 16 • 18+ years • H1 - antihistamine - failed • Inadequate response to omalizumab UAS7 measured at 12 weeks (Primary Endpoint) • US Lead: Tom Casale
Slide 16: Briquilimab Phase 1b/2a in patients with CIndU
16 Briquilimab is an investigative drug and is not approved for any indication Briquilimab Phase 1b/2a in patients with Chronic Inducible Urticaria (CIndU) Study Goal: identify therapeutic doses of subcutaneous briquilimab to inform future registrational trials Key Objectives: • Demonstration of eff
Slide 17: Briquilimab Phase 1b/2a Chronic Inducible Urticaria study design
17 Briquilimab is an investigative drug and is not approved for any indication 40 mg 120 mg Single Dose 36 - Week Follow - Up N=15 • Diagnosis of Cold Urticaria (ColdU) or Symptomatic Dermographism (SD) for ≥ 3 mos. • H1 - antihistamine - failed • 18+ years Provocation test measured at 12 weeks (Pri
Slide 18: Mast cell depletion may provide deep and durable disease control
18 Briquilimab is an investigative drug and is not approved for any indication Mast cell depletion may provide deep and durable disease control with a convenient dosing schedule 1 Kolkhir P et al. Nature Reviews Disease Primers (2022) 2 Characterized by complete response and overall effects on disea
Slide 19: Briquilimab is designed for differentiated mast cell depletion
19 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is designed for differentiated mast cell depletion Potency • Binding affinity : K d < 5pM • Target epitope : Direct blockade of SCF binding pocket on c - Kit triggers mast cell apoptosis through the Bim pathwa
Slide 20: Engineering c-Kit enables in vivo testing in mast cell disease models
20 Briquilimab is an investigative drug and is not approved for any indication Engineering c - Kit enables direct in vivo testing of briquilimab in mast cell mediated disease models • c - Kit antibodies designed against human receptor do not bind to wild type mouse c - Kit, thereby limiting disease
Slide 21: Depleting mast cells may drive therapeutic benefit across a broad range of diseases
21 Briquilimab is an investigative drug and is not approved for any indication Briquilimab’s ability to deplete mast cells may drive significant therapeutic benefits across a broad range of diseases Kolkhir P et al. Nature Reviews (2022) Mast Cell Driven Diseases These diseases are specifically caus
Slide 22: Briquilimab in Low-to-Intermediate Risk MDS & Bone Marrow Transplant
Briquilimab is an investigative drug and is not approved for any indication 22 22 Briquilimab in Low - to - Intermediate Risk MDS & Bone Marrow Transplant
Slide 23: Depleting cancerous stem cells as a disease-modifying therapeutic in LR-MDS
23 Briquilimab is an investigative drug and is not approved for any indication Briquilimab’s ability to directly deplete cancerous stem cells may be leveraged as a disease - modifying therapeutic in low - to - intermediate risk MDS patients 1 Greenberg PL, et al. Blood (2012) 2 Ma X, et al. Am J Med
Slide 24: Briquilimab Phase 1 trial in patients with LR-MDS
24 Briquilimab is an investigative drug and is not approved for any indication Briquilimab Phase 1 trial in patients with LR - MDS Normal HSCs MDS HSCs Briquilimab Restoration of healthy bone marrow following briquilimab treatment Single Arm, MAD, Open Label Design (Enrolling) • Dosing: Up to 4 coho
Slide 25: Briquilimab tested as a novel conditioning agent for bone marrow transplant
25 Briquilimab is an investigative drug and is not approved for any indication Briquilimab is also being tested as a novel conditioning agent for bone marrow transplant • Briquilimab c - Kit inhibition temporarily creates space in specialized bone marrow niches • May drive non - quiescent HSCs to di
Slide 26: Expanded portfolio presents new opportunities in mast cell diseases
26 Briquilimab is an investigative drug and is not approved for any indication Expanded portfolio presents exciting new opportunities in mast cell diseases Program Milestones Clinical Preclinical Research Sponsor Indication Briquilimab Mast Cell Diseases (Subcutaneous) • IND cleared; EU CTA submitte
Slide 27: Key milestones & financials
27 Briquilimab is an investigative drug and is not approved for any indication Key milestones & financials • $115.8M cash and cash equivalents as of June 30, 2023 • $16.1M net loss for Q2 2023 • 110.8M outstanding shares as of June 30, 2023 • 43 employees 2023 2024 Briquilimab (c - Kit) CSU CIndU LR
Slide 28: Developing briquilimab across multiple disease areas with 2024 data readouts
28 Briquilimab is an investigative drug and is not approved for any indication Jasper is developing briquilimab across multiple disease areas affecting millions of patients with key data read outs expected in 2024 • c - Kit mediated depletion of mast cells is a novel therapeutic approach that has th
Slide 29: Jasper Therapeutics October 2023
Briquilimab is an investigative drug and is not approved for any indication 29 Jasper Therapeutics NASDAQ: JSPR October 2023
Jasper Therapeutics — Investor Presentation (October 2023) on 6ix